CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 9 enrolled
Drug / intervention
Ropinirole (Requip)drug
Likely dose
Ropinirole (Requip) 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00334048
NCT00334048Phase 4Completed
CompareCT.gov

Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants

St. Luke's-Roosevelt Hospital Center·interventional·Posted Jun 6, 2006·Updated Feb 19, 2015

In Brief

A Phase 4 clinical trial evaluating Ropinirole (Requip) for Sexual Dysfunction. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip (ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunction
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2006
Enrollment StartJun 1, 2006
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.1 years ago

Interventions

Ropinirole (Requip)drug

1 mg extended release formulation given once per day to a maximum of 4 per day